Mustang Bio, Inc.
MBIO
$0.59
$0.00-0.08%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 20.20% | -27.69% | 542.60% | -31.64% | -48.60% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 32.20% | 318.18% | 2,676.92% | -57.17% | -84.98% |
| Operating Income | -32.20% | -318.18% | -2,676.92% | 57.17% | 84.98% |
| Income Before Tax | -40.68% | -524.18% | 43.49% | 66.81% | 90.71% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -40.68% | -524.18% | 43.49% | 66.81% | 90.71% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -40.68% | -524.18% | 43.49% | 66.81% | 90.71% |
| EBIT | -32.20% | -318.18% | -2,676.92% | 57.17% | 84.98% |
| EBITDA | -31.24% | -379.22% | -970.13% | 55.62% | 84.22% |
| EPS Basic | 15.99% | -165.23% | 90.75% | 96.17% | 98.97% |
| Normalized Basic EPS | 15.96% | -165.57% | -196.83% | 96.16% | 98.48% |
| EPS Diluted | 15.99% | -165.23% | 90.75% | 96.17% | 98.97% |
| Normalized Diluted EPS | 15.96% | -165.57% | -196.83% | 96.16% | 98.48% |
| Average Basic Shares Outstanding | 67.43% | 135.24% | 510.99% | 765.82% | 800.43% |
| Average Diluted Shares Outstanding | 67.43% | 135.24% | 510.99% | 765.82% | 800.43% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |